安必力®

Search documents
新股消息 | 海西新药通过港交所聆讯 四款仿制药入选国家带量采购计划
智通财经网· 2025-09-29 22:50
智通财经APP获悉,据港交所9月29日披露,福建海西新药创制股份有限公司(以下简称:海西新药)通过港交 所主板上市聆讯,华泰国际和招银国际为其联席保荐人。 安必力®于2024年为公司贡献收益人民币1.46亿元,根据灼识咨询的资料,在中国以25.7%的市场份额在其产 品类别中排名第二 | [編纂]數目 | | : [編纂]股H股(視乎[編纂]行使與否而定) | | --- | --- | --- | | [編纂]數目 | .. | [編纂]股H股(可予[編纂]) | | [編纂]數目 | | : [編纂]股H股(可予[編纂]及視乎[編纂]行使 | | | | 與否而定) | | 最高[編纂] | .. | 每 股H 股[編纂]港元,另 加1.0%經紀佣金、 | | | | 0.0027%證監曾交易徵費、0.00565% 香港聯 | | | | 交 所 交 易 費 以 及 會 計 及 0.00015% 財 務 匯 報 | | | | 局交易 徽 費(須 於 申 請 時 以 港 元 繳 足,視 | | | | 乎最終定價可予退還) | | | | Associate 25 PS PS PS 25 25 2000 3 ...
新股前瞻|从仿制到创新:海西新药如何平衡现金流与研发投入?
智通财经网· 2025-08-11 23:33
Core Viewpoint - The trend of pharmaceutical companies seeking to list on the Hong Kong Stock Exchange continues, with HaiXi New Drug being a notable example, having submitted its application again after an initial attempt earlier in the year [1][2]. Company Overview - HaiXi New Drug is a commercial-stage pharmaceutical company with a diversified product portfolio and pipeline, having achieved significant growth compared to many peers still in clinical stages [1][2]. - The company has received approval for 14 generic drugs from the National Medical Products Administration and has four innovative drugs in its pipeline, positioning it as a major player in China's pharmaceutical industry [2][4]. Financial Performance - The company reported revenues of approximately 2.5 billion RMB over five months, with a significant portion of revenue coming from a major client [2][5]. - Revenue figures for the reporting period show a growth trend: 212 million RMB in 2022, 317 million RMB in 2023, and projected 467 million RMB in 2024, with profits also increasing correspondingly [5][6]. - The company heavily relies on a few major clients, with the top five clients contributing 71.7% to 85.1% of total revenue during the reporting periods [7]. Business Model - HaiXi New Drug operates a light-asset model, utilizing the Marketing Authorization Holder (MAH) system, which separates drug marketing and production licenses, allowing for outsourcing of production [5][10]. - The company has established a sales and distribution network with over 18,000 hospitals and medical institutions across China, covering all provinces and municipalities [4]. Market Strategy - The company is focusing on both generic and innovative drugs, with a particular emphasis on developing small-molecule innovative drugs that meet clear clinical needs [4][12]. - HaiXi New Drug's innovative pipeline includes a potential first-in-class oncology drug and other drugs targeting significant market needs, indicating a strategic shift towards innovation [12][14]. Industry Context - The Chinese pharmaceutical market is predominantly composed of generic drugs, with over 90% of the 4,000 pharmaceutical companies being generic drug manufacturers [11]. - The global market for breast cancer drugs is projected to grow significantly, providing a substantial opportunity for HaiXi New Drug's innovative products [12]. Future Outlook - The company is transitioning towards a heavier asset model with the construction of its own manufacturing facility, which may lead to increased operational volatility [14]. - Balancing stable income from generics with the long-term investment required for innovative drug development will be crucial for the company's future valuation [14].
海西新药“持证卖药”暴涨200%,账面资金仅3800万
阿尔法工场研究院· 2025-08-08 00:07
Core Viewpoint - Haixi New Drug, the first pharmaceutical company in Fujian to obtain a drug production license, is advancing its IPO process on the Hong Kong Stock Exchange, showcasing significant revenue growth but facing various operational risks [1][2]. Financial Performance - Haixi New Drug's revenue surged from 2.12 billion in 2022 to 4.67 billion in 2024, with a net profit increase from 690 million to 1.36 billion during the same period, reflecting a compound annual growth rate (CAGR) of 48.2% for revenue and 40.5% for net profit [4]. - In the first five months of 2025, the company reported revenue of 2.49 billion and a net profit of 902 million [4][20]. Revenue Dependence and Risks - The company heavily relies on 13 approved generic drugs, with 4 included in the national volume-based procurement (VBP) program, leading to a significant dependency on VBP products, which accounted for 72.6% of revenue in 2024 [6]. - The top five customers contributed over 70% of total revenue, with the largest customer accounting for 44.5% [6]. - Key VBP products are approaching contract expiration, with two set to expire by the end of 2025 and others in subsequent years, raising concerns about future revenue stability [6][7]. Cash Flow and Financial Health - Despite impressive revenue growth, the company's cash flow is under pressure, with a cash balance of only 380 million at the end of 2024, covering just 21% of current liabilities [15][21]. - The operating cash flow has shown fluctuations, with a net cash flow of 1.64 billion in 2024, but a decline to 800 million in the first five months of 2025 [11]. Sales and Marketing Expenses - The sales expense ratio increased from 22% in 2022 to 35.5% in 2024, significantly higher than the industry average, which may erode profit margins [12][13]. - The rising sales costs are attributed to increased channel maintenance expenses and the need for additional marketing resources for newly included VBP products [12]. Innovation Pipeline - Haixi New Drug has four innovative drugs in development, but all are in early stages, with the first clinical trials just starting [17][19]. - The company’s R&D expenditure is relatively low, with rates below the industry threshold of 20%, which may hinder future innovation [19][23]. - The company plans to use funds from the IPO to support clinical development and expand its sales network, but faces competition from established products that are already ahead in the market [24]. Production Capacity Concerns - The company’s production facility in Chang Le has a designed capacity of 2 billion tablets per year, but actual sales in 2024 were only 460 million tablets, raising concerns about potential overcapacity [25].
海西新药招股书解读:营收增长47.4%,市场地位与风险并存
Xin Lang Cai Jing· 2025-08-07 00:24
来源:新浪港股-好仓工作室 福建海西新药创制股份有限公司是一家处于商业化阶段的制药公司,正冲刺港股IPO。此次招股书展现 了公司在业务、财务等多方面的情况,其中营收增长47.4%颇为亮眼,但同时也隐藏着一些风险点,值 得投资者关注。 业务模式:双轨并行,各有千秋 仿制药:市场地位初显 公司2024年收入增长远超过中国医药市场平均增长,增长率高达47.4% 。这主要得益于仿制药入选VBP 计划带来的销量增长。从产品来看,入选国家VBP计划的几款药物贡献突出,如海慧通®、安必力® 等。 净利润:暂未披露变化情况 招股书中未明确提及净利润的具体变化数据。净利润受多种因素影响,包括成本控制、销售费用、研发 投入等。在营收增长的情况下,净利润的走向对公司盈利能力评估至关重要,投资者需后续关注相关信 息披露。 毛利率与净利率:数据待明确 海西新药通过推出一系列技术壁垒高、市场潜力大且符合监管要求的仿制药,在市场上确立了一定地 位。截至最后实际可行日期,公司已就14款仿制药获得国家药监局批准 。其中,有四款入选国家带量 采购("VBP")计划,四款入选省级VBP计划。像安必力®被视为通过中国一致性评价并率先进入市场 的枸橼 ...